Vol 9, No 6 (December 2020): Chinese Clinical Oncology

Editorial on Targeted Systemic Therapies for Primary and Metastatic Brain Tumors1

Targeted systemic therapies for primary brain tumors
Lyndon Kim

Review Article on Targeted Systemic Therapies for Primary and Metastatic Brain Tumors1

Target treatment with stereotactic radiation for recurrent gliomas
Ayesha S. Ali, Victor E. Chen, Claire Zurlo, James M. Taylor, Christian Fernandez, Wenyin Shi
A narrative review of targeted therapy in meningioma, pituitary adenoma, and craniopharyngioma of the skull base
Nina L. Martinez, Omaditya Khanna, Christopher J. Farrell
A narrative review of targeted therapies in meningioma
Lyndon Kim
Characterization of molecular pathways for targeting therapy in glioblastoma
Naveed Wagle, Minhdan Nguyen, Jose Carrillo, Judy Truong, Lucia Dobrawa, Santosh Kesari

Original Article

Real-world assessment of the effect of impact of tumor size on pathological complete response rates in triple negative breast cancer after neoadjuvant chemotherapy
Bruno Henrique Rala de Paula, Sanjeev Kumar, Fabiola Marques Morosini, Debora Evelyn Martins Calábria Cardoso, Carlos Augusto Moreira de Sousa, Susanne Crocamo

Letter to the Editor

Collateral damage of COVID-19 pandemic on oncology clinical trials
Sri Harsha Tella, Anuhya Kommalapati, Steve R. Alberts, Robert McWilliams, Amit Mahipal

Editorial Commentary

Indolent non-Hodgkin lymphoma treatment in the new drugs era
Luis Miguel Juárez-Salcedo, Samir Dalia
Real-world applications of deep convolutional neural networks in diagnostic cancer imaging
Hesham Elhalawani, Pei Yang, Mohamed Abazeed, Chirag Shah, Abdallah S. R. Mohamed, Charles R. Thomas Jr, Clifton D. Fuller, Reid F. Thompson
Ramucirumab treatment in hepatocellular carcinoma
Federico Longo, Alfredo Carrato
Moving toward multi-dimensional biomarkers in cancer immunotherapy
Max Jameson-Lee, Jason J. Luke

Disclosure:

1. The series “Targeted Systemic Therapies for Primary and Metastatic Brain Tumors” was commissioned by the Editorial office, Chinese Clinical Oncology without any sponsorship or funding. Jon Glass served as the unpaid Guest Editor for the series.